We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.
- Authors
Fritz, Megan Kunka; Mangino, Anthony A.; Hunt, Taylor V.; Pitcock, C. Tyler; Dugan, Adam J.; Karri, Kishore; Yarra, Pradeep
- Abstract
Background: Additional therapies for hepatic encephalopathy (HE) treatment are warranted. There are data evaluating the use of zinc for HE; however, clinical outcomes, specifically in the United States, are unknown. Objective: To compare 30-day and 1-year all-cause readmission rates in patients with cirrhosis complicated by HE on lactulose and rifaximin to those on lactulose, rifaximin, and zinc. Methods: This retrospective study included patients admitted with documented cirrhosis and home medications of lactulose and rifaximin, with or without zinc. Patients were stratified into 2 groups: those receiving lactulose and rifaximin for HE (control) and those receiving lactulose, rifaximin, and zinc for HE (treatment). The primary outcomes were 30-day and 1-year all-cause readmission rates. Results: One-hundred fifty-seven patients were included (102 in control group, 55 in treatment group). Regarding 30-day and 1-year all-cause readmission rates, there was no difference between the control and treatment groups. Conclusion and Relevance: This is the first study conducted in the United States evaluating zinc for HE treatment. Zinc did not impact 30-day or 1-year all-cause readmission rates. Further studies are warranted to evaluate the potential benefit of zinc for HE, possibly in correlation with Model for End-stage Liver Disease-Sodium (MELD-Na) scores.
- Subjects
UNITED States; HEPATIC encephalopathy; ZINC; TREATMENT effectiveness; RIFAXIMIN; LACTULOSE
- Publication
Annals of Pharmacotherapy, 2023, Vol 57, Issue 8, p899
- ISSN
1060-0280
- Publication type
Article
- DOI
10.1177/10600280221134283